Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026)
Quarterly Total Non-Current Liabilities rose 44.62% to $60.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.2 million through Mar 2026, up 44.62% year-over-year, with the annual reading at $66.9 million for FY2025, 75.18% up from the prior year.
Structure Therapeutics' Total Non-Current Liabilities history spans 5 years, with the latest figure at $60.2 million for Q1 2026.
- Total Non-Current Liabilities came in at $60.2 million for Q1 2026, down from $66.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $66.9 million in Q4 2025 to a low of $13.0 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $37.1 million (2024), against an average of $38.9 million.
- Year-over-year, Total Non-Current Liabilities soared 119.45% in 2023 and then skyrocketed 33.74% in 2024.
- Structure Therapeutics' Total Non-Current Liabilities stood at $13.0 million in 2022, then skyrocketed by 119.45% to $28.6 million in 2023, then surged by 33.74% to $38.2 million in 2024, then soared by 75.18% to $66.9 million in 2025, then dropped by 10.06% to $60.2 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Total Non-Current Liabilities are $60.2 million (Q1 2026), $66.9 million (Q4 2025), and $61.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | 60.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.17 Mn |
| Dec 31, 2025 | 66.89 Mn |
| Sep 30, 2025 | 61.82 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | 41.60 Mn |
| Dec 31, 2024 | 38.19 Mn |
| Sep 30, 2024 | 36.11 Mn |
| Jun 30, 2024 | 25.70 Mn |
| Mar 31, 2024 | 27.11 Mn |
| Dec 31, 2023 | 28.55 Mn |
| Sep 30, 2023 | 23.13 Mn |
| Dec 31, 2022 | 13.01 Mn |